This dual chemo-immunotherapy remodels the suppressive tumor microenvironment, enhancing CD8+ T-cell infiltration, reducing Treg recruitment, and suppressing tumor growth in KPC mice without inducing overt systemic toxicity (Fig. 3C) [51]. This evidence concerns the gene CD8A and neoplasm.